









This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1002/1878-0261.12467 
Molecular Oncology (2019) © 2019 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
This is an open access article under the terms of the Creative Commons Attribution License, 
which permits use, distribution and reproduction in any medium, provided the original work 
is properly cited. 
DR. FEDERICA  DI NICOLANTONIO (Orcid ID : 0000-0001-9618-2010) 
 
Received Date : 31-Oct-2018 
Revised Date   : 11-Jan-2019 
Accepted Date : 19-Jan-2019 
Article type      : Review 
 
Exploiting DNA repair defects in colorectal cancer 
 
Nicole M. Reilly1, Luca Novara2, Federica Di Nicolantonio2,3, and Alberto Bardelli2,3* 
 
1Fondazione Piemontese per la Ricerca sul Cancro ONLUS, Candiolo, TO, Italy  
2Candiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy 
3Department of Oncology, University of Torino, SP 142 km 3.95, 10060 Candiolo, TO, Italy 
 
*To whom correspondence should be addressed: 
Alberto Bardelli 
Department of Oncology, University of Torino, SP 142 km 3.95, 10060 Candiolo, TO, Italy 
Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, TO, Italy 
Tel: +39 011 993 3235. Fax: +39 011 993 3225  
Email address: alberto.bardelli@unito.it 
 











Molecular Oncology (2019) © 2019 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
Keywords: colorectal cancer, mismatch repair, homologous recombination, microsatellite 
instability, genome instability 
 
Abbreviations: ATRi: ataxia telangiectasia mutated and Rad3 related inhibitors, BER: base 
excision repair, CHK1i: checkpoint kinase 1 inhibitors, CRC: colorectal cancer, DDR: DNA 
damage response, FA: Fanconi Anemia, HR: homologous recombination, MSI: microsatellite 




Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide. 
Therapies that take advantage of defects in DNA repair pathways have been explored in the 
context of breast, ovarian, and other tumor types, but not yet systematically in CRC. At 
present, only immune checkpoint blockade therapies have been FDA approved for use in 
mismatch repair deficient colorectal tumors.  Here, we discuss how systematic identification 
of alterations in DNA repair genes could provide new therapeutic opportunities for CRCs. 
Analysis of The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) and Rectal 
Adenocarcinoma (TCGA-READ) PanCancer Atlas datasets identified 141 (out of 528) cases 
with putative driver mutations in 29 genes associated with DNA damage response and 
repair, including the mismatch repair and homologous recombination pathways. Genetic 
defects in these pathways might confer repair-deficient characteristics, such as genomic 
instability in the absence of homologous recombination, which can be exploited. For 
example, inhibitors of poly(ADP)-ribose polymerase are effectively used to treat cancers that 
carry mutations in BRCA1 and/or BRCA2, and have shown promising results in CRC pre-
clinical studies. HR deficiency can also occur in cells with no detectable BRCA1/BRCA2 
mutations but exhibiting BRCA-like phenotypes. DNA repair-targeting therapies, such as 
ATR and CHK1 inhibitors (which are most effective against cancers carrying ATM 
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further improve therapy response. Finally, therapies that target alternative DNA repair 
mechanisms, such as thiopurines, also have the potential to confer increased sensitivity to 
current chemotherapy regimens, thus expanding the spectrum of therapy options and 
potentially improving clinical outcomes for CRC patients.  
 
1 Introduction 
Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading 
cause of cancer related deaths (Bray, Ferlay et al. 2018). In Europe, CRC accounts for the 
second highest number of cancer cases and deaths (Malvezzi, Carioli et al. 2018), and in 
North America CRC has the fourth highest rate of incidence and the second highest number 
of cancer-related deaths (Jemal, Ward et al. 2017). While CRC death rates are slowly 
declining in the United States and Europe (Jemal, Ward et al. 2017, Malvezzi, Carioli et al. 
2018), the five-year overall survival for patients with metastatic CRC (mCRC) remains poor 
(approximately 14.0% (NCI 2017)). The standard chemotherapeutic regimen for mCRC is 5-
fluorouracil (5-FU) in combination with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) 
(Cremolini, Schirripa et al. 2015). These chemotherapy agents induce genotoxic damage in 
tumor cells that is recognized and repaired by DNA repair proteins (Helleday, Petermann et 
al. 2008).  
 In 2012, The Cancer Genome Atlas (TCGA) conducted a comprehensive 
characterization of CRC tumors, including exome sequences, DNA copy numbers, and RNA 
expression levels (Network 2012). Of the cases analyzed, 16% were classified as 
hypermutated (greater than 12 mutations per 106 bases) and exhibited mutation enrichment 
in microsatellite regions indicating microsatellite instability (MSI) phenotype. The other 84% 
of cases were classified as microsatellite stable (MSS), and exhibited a higher frequency of 
somatic copy number alterations, suggesting chromosomal and sub-chromosomal defects 
(Network 2012). The most frequently identified gene mutations in CRC tumors occur in APC, 
TP53, and KRAS (Huang, Sun et al. 2018, Wolff, Hoffman et al. 2018, Yaeger, Chatila et al. 
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response genes and found that cases in the colon adenocarcinoma (COAD) and rectal 
adenocarcinoma (READ) datasets carried mutations in several DNA damage response and 
repair (DDR) genes (Knijnenburg, Wang et al. 2018). 
 Acquisition of mutations is a critical step for tumor development (Hanahan and 
Weinberg 2011), and mutations that occur in DNA repair genes impair cells’ ability to restore 
damaged DNA and can lead to cell death or genome instability (Aguilera and Gomez-
Gonzalez 2008). Mutations in MMR genes are observed in 2 – 3% of CRC patients (Lorans, 
Dow et al. 2018), while approximately 10% of CRC patients exhibit hypermethylation of 
MLH1 (Pearlman, Frankel et al. 2017, AlDubayan, Giannakis et al. 2018), contributing to a 
MMR-deficient (MMRd) phenotype. The remaining CRC patient population can be classified 
as MMR-proficient (MMRp).  Defects in the MMR pathway are commonly used to classify 
CRCs, while mutations in HR and FA genes have been historically linked with breast and 
ovarian cancers (Knijnenburg, Wang et al. , Hoang and Gilks 2018). The TCGA-COAD and -
READ PanCancer Atlas cohort (Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013, Liu, 
Lichtenberg et al. 2018) includes mutational data for 528 patient tumor samples, and 
analysis of these samples identified 141 cases that carried mutations in at least one of 420 
DNA repair genes. The majority of mutations identified were classified as “putative 
passenger.” While these mutations are not currently known to drive carcinogenesis, it is 
possible that the presence of these mutations will cause the cells to be DNA repair-deficient. 
Using criteria that excluded likely passenger mutations, putative driver mutations were 
identified in 29 DNA damage response and repair genes (Table 1).   
Epigenetic modulation of gene expression can also lead to a repair-defective 
phenotype. For example, hypermethylation of the MLH1 promoter has been associated with 
the MSI phenotype in sporadic endometrial and hereditary nonpolyposis colorectal cancers 
(Esteller, Levine et al. 1998, Planck, Ericson et al. 2003, Niv 2007). Epigenetic down-
regulation of MMR genes has also been linked with resistance to alkylating chemotherapy 
agents in CRC tumor models (Planck, Ericson et al. 2003), and studies have demonstrated 
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agents (Francia, Green et al. 2005). Methylation data was not available for the PanCancer 
Atlas dataset; however, analysis of the TCGA-COADREAD Provisional dataset (Cerami, 
Gao et al. 2012, Gao, Aksoy et al. 2013) determined that 10.3% of cases (37 out of 358) 
exhibited hypermethylation of MLH1. The presence of mutations or hypermethylation of 
promoter regions in one or more DNA repair genes in a CRC cell may contribute to a DNA 
repair defective phenotype that can be used to classify tumor sub-types and to choose an 
appropriate therapy regimen. 
 
2 DNA repair-defective phenotypes in colorectal cancers 
2.1 Mismatch repair 
The MMR pathway recognizes and removes DNA base pair mismatches that occur due to 
replication errors (Iyer, Pluciennik et al. 2006, Modrich 2006) (Figure 1; left panel). First, the 
mismatch is recognized by MutSα (MSH2/MSH6) and MutLβ (MLH1/PMS1) or MutSβ 
(MSH2/MSH3) and MutLα (MLH1/PMS2) heterodimer complexes that bind the DNA 
surrounding the mismatch. Downstream, the exonuclease EXO1 interacts with proliferating 
cell nuclear antigen (PCNA), initiating DNA resection in a 5´ to 3´ manner. Finally, 
polymerase δ replicates across the excised region and the DNA is ligated by DNA ligase I. 
Inactivating mutations in any of these genes decreases recognition of base pair mismatches, 
leading to increased mutational burden, particularly in microsatellite regions of the genome 
(Popat, Hubner et al. 2005, Hause, Pritchard et al. 2016, Cortes-Ciriano, Lee et al. 2017). 
One of the phenotypes exhibited in MMRd cells is MSI (Zeinalian, Hashemzadeh-
Chaleshtori et al. 2018), and several studies have shown that MSI corresponds with 















Molecular Oncology (2019) © 2019 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
2.1.1 Microsatellite instability 
A phenotype of cells that carry defects in mismatch repair is microsatellite instability (MSI), 
defined as high mutational burden in sequences along the genome that contain repetitive, 
short-tandem sequences containing 1–6 nucleotide units up to 100 times, known as 
microsatellites (Zeinalian, Hashemzadeh-Chaleshtori et al. 2018). The National Institutes of 
Health has defined five biomarkers that contain mono- or dinucleotide repeats in specific 
regions of the genome to be used for clinical determination of MSI status (Boland, 
Thibodeau et al. 1998). PCR amplification of biomarker regions is performed, and the 
product size in tumor cells is compared with matched normal cells to determine if mutations 
are present (Zeinalian, Hashemzadeh-Chaleshtori et al. 2018). New advents in sequencing 
technology has allowed for the detection of MSI using whole-exome sequencing (WES) data 
from tumor samples and normal tissue isolated from the same patient (Hause, Pritchard et 
al. 2016). A comprehensive analysis of microsatellite stability in 5,930 exome samples 
demonstrated that these strategies are capable of distinguishing MSI cancer from MSS 
cancers, and these analyses identified genomic ‘hot spots’ that exhibit higher frequencies of 
MSI across cancer sub-types (Hause, Pritchard et al. 2016). Immunohistochemistry using 
antibodies against MLH1, MSH2, MSH6, and PMS2 is another effective technique that is 
used to assess MMR status (Yuan, Chi et al. 2015, Zeinalian, Hashemzadeh-Chaleshtori et 
al. 2018). 
Generation of neoantigens is another phenotype of MMRd cells that has been well-
characterized in CRC (Scarpa, Ruffolo et al. 2015, Germano, Lamba et al. 2017, Le, Durham 
et al. 2017). The defects in MMR machinery lead to frameshifts and indels that produce 
novel peptides within a cell. Once translated, these peptides can be exposed to the outside 
of the cell by the HLA proteins and activate immune surveillance of the tumor cells, thus 
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2.2 Homologous recombination  
The HR pathway is essential for preserving genome integrity in the event of DNA double 
strand breaks (DSBs) (Ranjha, Howard et al. 2018) (Figure 1; right panel). If left unrepaired, 
this type of damage can lead to deletions, frameshifts, chromosome aberrations, and 
aneuploidy (Jackson and Bartek 2009). During S phase, a DSB is first recognized by 
poly(ADP-ribose) polymerase 1 (PARP1), a protein that scans the genome and detects DSB 
lesions (Ciccia and Elledge 2010). PARP1 marks the damage site by attaching ADP-ribose 
molecules to chromatin-bound proteins surrounding the break (Haince, McDonald et al. 
2008). The ADP-ribose units are essential for recruitment of meiotic recombination 11 
(MRE11), RAD50, and Nijmegen Breakage Syndrome (NBS1) proteins, which form the MRN 
complex. The exonuclease activity of this complex produces single strand DNA (ssDNA) 
surrounding the break (Haince, McDonald et al. 2008, Dodson, Limbo et al. 2010, Huen, Sy 
et al. 2010, You and Bailis 2010), and localization of MRN triggers ATM-mediated signaling 
of downstream repair factors. Following MRN-mediated resection, the single strand binding 
protein replication protein A (RPA) stabilizes the newly produced ssDNA overhangs 
(Marechal and Zou 2015). Recruitment of BRCA1 and BRCA2, along with BRIP1, PALB2, 
and the RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex, promotes RAD51 binding to 
the ssDNA overhangs (Jensen, Ozes et al. 2013, Candelli, Holthausen et al. 2014, Short, Liu 
et al. 2016, Xu, Zhao et al. 2017). Finally, RAD51 mediates strand invasion of the ssDNA 
overhang into a homologous DNA region, usually a sister chromatid, enabling repair to be 
completed (Qi, Redding et al. 2015). 
 
2.2.1 Genome instability 
In the context of distinct cancers types, such as breast and ovarian, ‘genome instability’ is 
typically attributed to defects in HR DNA repair genes (Janssen, van der Burg et al. 2011, 
Burrell, McClelland et al. 2013, Chien, Sicotte et al. 2015, Vanderstichele, Busschaert et al. 
2017). Hanahan and Weinberg classified ‘genome instability’ as an enabling characteristic of 
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the telomere region (Hanahan and Weinberg 2011). Genome instability is identified by 
structural alterations that include copy number variations and loss-of-heterozygosity, often 
observed in CRC cells (Druliner, Ruan et al. 2018), and chromosomal rearrangements 
(Aguilera and Gomez-Gonzalez 2008). These elements are characteristic of HR defective 
cells, and specific genomic signatures have been identified in breast and ovarian cancer 
cells (Davies, Glodzik et al. 2017, Vanderstichele, Busschaert et al. 2017, Hillman, Chisholm 
et al. 2018). The detection of genomic rearrangements by whole-genome sequencing in 
BRCA1/BRCA2 deficient samples lead to identification of six distinct mutational signatures 
that correlated with BRCA status (Davies, Glodzik et al. 2017). Notably, the so-called BRCA-
ness signature was also identified in cells that did not have detectable BRCA1/BRCA2 
mutations, connecting genomic rearrangements with functional HR-deficiency, and 
suggesting that additional molecular alterations might underline BRCA-like phenotypes 
(Davies, Glodzik et al. 2017). BRCA-ness mutational signatures in CRC tumors might be 
used as predictive biomarkers for HR-deficiency regardless of BRCA status.  
 
2.2.2 Telomere defects  
In addition to genomic rearrangements, telomere length is a measurement of genome 
instability (Hackett, Feldser et al. 2001). HR repair proteins function to protect telomere 
regions from damage (Tarsounas, Munoz et al. 2004, Claussin and Chang 2015), and 
telomere defects are often observed in genome unstable cells (Venkatesan, Natarajan et al. 
2015). A recent study investigating telomere length in CRC determined that KRAS mutated 
cells exhibited extensive telomere shortening compared with control cells. In contrast, cells 
that carried BRAF mutations or were classified as MSI did not exhibit telomere defects 
(Balc'h, Grandin et al. 2017). Another independent study analyzed telomere length in 
precursor colorectal lesions and observed that telomere shortening was associated with 
mitochondrial microsatellite instability in the tumor tissue samples, and with KRAS and 
BRAF mutations in the normal tissues (Park, Bae et al. 2017). Studies have also 
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repair (Kalimutho, Bain et al. 2017), a key protein in the HR pathway that is essential for 
maintaining telomere integrity (Le, Moore et al. 1999, Signon, Malkova et al. 2001, Badie, 
Escandell et al. 2010, Lu, Pal et al. 2014). Together, these data suggest that telomere 
shortening is indicative of DNA repair defects and may be a biomarker of early CRC 
carcinogenesis.   
 
3 Targeting DNA repair in colorectal cancer 
Current medical regimens for CRC patients include combination therapies with oxaliplatin, 
irinotecan, and 5-FU (Cremolini, Schirripa et al. 2015). These ‘genotoxic’ drugs directly or 
indirectly induce DNA damage that is recognized by specific repair pathways (Figure 2). 
Oxaliplatin is a platinum-based compound that can induce cell death through several 
mechanisms, such as inducing ribosome biogenesis stress (Bruno, Liu et al. 2017). The 
genotoxic activity of this drug is attributed to its ability to bind the N7 of guanine nucleotides 
in DNA, generating inter-strand crosslinks that can inhibit replication during S phase (Ray, 
Gupta et al. 2018). Irinotecan, a camptothecin analog, binds to topoisomerase I and DNA, 
preventing dissociation of topoisomerase I during S phase and ultimately leading to DNA 
DSBs (Li, Jiang et al. 2017). These two types of DNA damage are recognized and repaired 
by the FA/HR pathways (Ceccaldi, Sarangi et al. 2016). 5-FU is an antimetabolite that 
inhibits thymidylate synthase, an enzyme involved in nucleotide synthesis, and is thought to 
inhibit DNA replication thus leading to abasic sites that are repaired by base excision repair 
(BER) proteins (Huehls, Huntoon et al. 2016). 5-FU can also be incorporated into DNA, 
resulting in DNA mismatches that are recognized and repaired by the MMR pathway 
(Iwaizumi, Tseng-Rogenski et al. 2011).  An alternative nucleotide analog, TAS-102, has 
been approved by the FDA as a treatment option for mCRC patients (Marcus, Lemery et al. 
2017). TAS-102 inhibits nucleoside synthesis in a similar mechanism of action to the 
standard therapy 5-FU, and is effective in treating patients that are refractory to 5-FU 
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genes, specifically those associated with HR, as predictive markers of the efficacy of TAS-
102 in patients (Suenaga, Schirripa et al. 2017). 
 These compounds are most effective in cells with defects in the respective repair 
pathways, and CRC patients that carry mutations in repair-associated genes can be 
predicted to respond well to these types of therapies.  
 
3.1. Immune checkpoint blockade 
CRC tumors that have increased neoantigen production due to MMR-deficiency also have 
higher levels of tumor infiltrating lymphocytes (TILs) and increased programmed death 
ligand-1 (PDL-1) protein expression (Llosa, Cruise et al. 2015, Kim, Park et al. 2016, 
Germano, Amirouchene-Angelozzi et al. 2018). Recent studies have shown that MSI tumor 
cells are responsive to PD-1 and CTLA-4 immune blockade (McGranahan, Furness et al. 
2016, Germano, Lamba et al. 2017, Le, Durham et al. 2017, Luksza, Riaz et al. 2017). In 
one study, patients with higher TILs and PD-L1 expression responded to checkpoint 
blockade better compared with patients with lower PD-L1 expression, suggesting that this 
phenotype can be used as a predictor of therapy response (Wang, Gong et al. 2018).  A 
2017 Phase II clinical trial of nivolumab, a PD-L1 immune checkpoint inhibitor, in patients 
with MMRd and MSI-H CRC who had received at least three rounds of prior therapy and 
were no longer responsive to first-line treatments found that this therapy provided durable 
response and disease control in these patients. Of the 74 patients enrolled, 31% achieved 
objective response and 51% achieved disease control (Overman, Lonardi et al. 2018). 
Based on these data, nivolumab was given FDA approval for the treatment of mCRC with 
MSI-H or MMRd tumors (Sarshekeh, Overman et al. 2018). In addition to CRC, studies have 
demonstrated that solid tumors of multiple tissue types exhibiting MSI show durable 
response to PD-L1 blockade, and based on this evidence, the FDA approved these agents 
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 MMRd tumors have increased mutational burden (TMB), a phenotype that can also 
be observed in a small subset of tumors that are MSS. One study analyzed over 6,000 CRC 
cases, 95% of which were classified as MSS, and observed that 2.9% of MSS tumors 
exhibited high TMB and, within this subset of tumors, 54% responded to anti PD-L1 
immunotherapy (Fabrizio, George et al. 2018). The results of this study suggest that in 
MMRd tumors that do not exhibit MSI, TMB can be used as a predictor for therapy response 
to tumor checkpoint inhibition.  
 
3.2 PARP inhibitors  
In the presence of directly induced DNA breaks, PARP1 poly(ADP-ribosyl)ates chromatin 
surrounding the damage to initiate activity of downstream HR proteins (Haince, McDonald et 
al. 2008). Additionally, PARP functions to regulate replication fork progression and maintain 
fork stability. Chemical inhibition of PARP activity can interfere with either of these activities, 
leading to replication fork collapse or accelerated fork progression that generates DNA 
single and double strand breaks (D'Andrea 2018, Maya-Mendoza, Moudry et al. 2018). Poly-
(ADP) ribose polymerase inhibitors (PARPi) have been used as anticancer agents since the 
early 2000’s (McCabe, Turner et al. 2006), and the first PARPi, olaparib, was approved for 
BRCA mutated ovarian cancer in 2014 (Kim, Ison et al. 2015). Approval of these drugs was 
first given for the treatment of breast and ovarian cancers, and studies found that this 
therapy regimen was most effective in cells that carry functional defects in DNA DSB 
pathways, most notably in BRCA mutated cells (Lin, Ratner et al. 2014, Ghiringhelli, Richard 
et al. 2016, Lord and Ashworth 2017, Cortesi, Toss et al. 2018, Mittica, Ghisoni et al. 2018, 
Sunada, Nakanishi et al. 2018). Recent studies ascribed this synthetic lethality phenotype to 
the loss of PARP activity at replication forks, suggesting that PARP inhibition promotes rapid 
fork progression, leading to increased genome instability that the cell cannot overcome when 
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Early investigations into the use of PARPi for the treatment of CRC began with the 
inhibitor ABT-888, later known as veliparib. Prior studies had demonstrated that ABT-888 
was effective in BRCA-deficient cells compared with proficient counterparts, and that 
response to PARPi was further increased when combined with platinum-based genotoxic 
compounds (Clark, Weitzel et al. 2012). Following on the premise that PARPi will increase 
sensitivity to genotoxic compounds in cancer cells, the effect of ABT-888 in combination with 
irinotecan in CRC cells was investigated (Davidson, Wang et al. 2013). This study observed 
a synergistic response to irinotecan or oxaliplatin in combination with ABT-888 in CRC cells 
(Davidson, Wang et al. 2013). Another study demonstrated that addition of ABT-888 
increased sensitivity of CRC cells to radiation (Shelton, Waxweiler et al. 2013), further 
supporting the hypothesis that PARPi are a viable option to improve response to current 
therapy regimens in CRC. A recent Phase II open label study evaluated the efficacy of the 
veliparib PARPi in combination with temozolomide in mCRC patients that were refractory to 
standard therapies. Fifty patients were enrolled in the trial, and 24% exhibited disease 
control response and 4% showed partial response to the combination therapy (Pishvaian, 
Slack et al. 2018).  
Synthetic lethality has been clearly demonstrated in cells that harbor defects in DNA 
DSB repair pathways, specifically BRCA mutated cells (McCabe, Turner et al. 2006, Lord 
and Ashworth 2017). For this reason, it can be predicted that CRC cells that respond well to 
PARPi most likely carry defects in DSB repair proteins. One study found that CRC cells 
carrying inactivating mutations in ATM have increased sensitivity to the PARPi olaparib 
(Wang, Jette et al. 2017). These data correlate well with earlier studies in gastric and lung 
cancers that found that loss of ATM protein expression increased cellular sensitivity to PARP 
inhibition (Kubota, Williamson et al. 2014, Schmitt, Knittel et al. 2017). However, due to the 
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In addition to exploiting DSB repair defects in CRC cells, it has been postulated that 
cells that exhibit MSI may also be susceptible to PARP inhibition. In 2014, a study 
demonstrated that loss of MRE11 in MSI CRC cells increased cellular sensitivity to ABT-888 
(Vilar, Bartnik et al. 2011). One proposed explanation is the MSI induces mutations within 
DNA repair genes, conferring a repair deficient phenotype and making the cells more 
susceptible to the effects of PARP inhibition. This hypothesis has been supported in models 
of myeloid malignancies (Gaymes, Mohamedali et al. 2013). More recently, a Phase II 
clinical trial investigated off-label of use of PARPi in MSS and MSI CRCs to determine if 
microsatellite status was a predictive marker of PARPi response. The results of this study 
suggested that PARPi alone did not affect patient outcomes regardless of microsatellite 
status (Leichman, Groshen et al. 2016). While PARPi have been approved for the treatment 
of other cancer types that exhibit HR deficiency, PARPi are not currently used for CRC 
patients.  
As discussed above, HR deficiency can also occur in cells with no detectable 
BRCA1/BRCA2 mutations but showing BRCA-like phenotypes. Accordingly, it will be of 
interest to assess whether the BRCA-ness mutational signatures might be used as predictive 
biomarkers for sensitivity to PARP inhibitors and oxaliplatin. 
 
3.2.1 DNA repair-mediated resistance mechanisms to PARP inhibition 
DNA repair associated resistance mechanisms to PARP inhibition have been well 
characterized in breast and ovarian cancers (D'Andrea 2018), and it is reasonable to predict 
that similar mechanisms may promote resistance in CRC patients following PARP blockade. 
One mechanism is re-activation of HR activity, either through acquired mutations in DNA 
repair genes or through increased activity of effector proteins that promote HR activity. 
Acquired mutations have also been described in HR genes that restore the reading frame 
and expression of the protein following exposure to PARPi (Quigley, Alumkal et al. 2017). 
Restoration of BRCA1 expression reverses HR-mediated repair deficiency and allows the 
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that restore activity of other HR proteins have also been observed in PARPi resistant cancer 
cells. A study of 12 pre-treatment and post-progression patient samples observed the 
acquisition of mutations in the RAD51D and RAD51C genes that restored protein expression 
and promoted resistance to rucaparib (Kondrashova, Nguyen et al. 2017), and an 
independent study identified a point mutation in the XRCC2 DNA repair gene that decreased 
sensitivity of CRC cells to olaparib (Xu, Song et al. 2014). In addition to mutations that 
restore gene expression, epigenetic regulation of gene expression can predict response and 
resistance to PARPi. In a study of 12 high grade serous ovarian cancer (HGSOC) patient-
derived xenografts and 21 patient samples (ARIEL2 trial), response and resistance to 
rucaparib was correlated with methylation status of BRCA1. Methylation-mediated silencing 
of all BRCA1 copies predicted response to rucaparib, while heterozygous methylation was 
associated with resistance to therapy (Kondrashova, Topp et al. 2018).  
HR activity can also be increased through regulatory effector proteins, such as the 
demethylase JMJD1C. This enzymes targets MDC1 for demethylation at Lys45 to promote 
its interaction with RNF8 and its function in the HR signalling cascade (Watanabe, Watanabe 
et al. 2013). Overexpression of JMJD1C has been detected in colon cancer tissues 
compared with normal tissues  (Chen, Aihemaiti et al. 2018). Furthermore, depletion of 
JMJD1C in cells induces cellular resistance to ionizing radiation (IR) and PARPi (Watanabe, 
Watanabe et al. 2013).  These data suggest that resistance mechanisms can arise from 
regulatory proteins in DNA repair pathways and further show that a comprehensive 
understanding of repair efficiency is necessary to properly predict therapy response.  
A second mechanism of PARPi resistance described in BRCA mutated cancers is 
increased activity of alternative DNA repair pathways. In the absence of BRCA1, activity of 
non-homologous end joining (NHEJ), an alternative DNA DSB repair pathway, is increased 
specifically through loss of p53 binding protein 1 (53BP1) expression (Bouwman, Aly et al. 
2010, Jaspers, Kersbergen et al. 2013). 53BP1 regulates pathway choice in response to 
DNA DSBs and promotes NHEJ activity through inhibition of BRCA1 recruitment during early 
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cancers lead to partial restoration of HR-mediated DSB repair and contributed to resistance 
to PARPi (Jaspers, Kersbergen et al. 2013). A recent study observed that cancer cells 
carrying mutations that lead to expression of a truncated BRCA1 protein, which maintained 
the ability to interact with PALB2, still developed PARPi resistance even in the absence of 
53BP1. In contrast, loss of the interaction between BRCA1 and PALB2 did not confer PARPi 
resistance when 53BP1 expression was decreased, suggesting that this protein interaction is 
required for any measurable HR activity (Nacson, Krais et al. 2018).  
Increased activity of NHEJ in the absence of BRCA1 can also be attributed to 
expression of REV7, the non-catalytic subunit of DNA polymerase ζ, which functions to 
promote translesion synthesis in the presence of DNA damage (Lee, Gregory et al. 2014). In 
response to DSBs, REV7 interacts with 53BP1 to prevent DNA-end resection at the break 
site. This activity promotes end-ligation mediated by NHEJ proteins and contributes to DSB 
repair following PARP inhibition (Xu, Chapman et al. 2015). REV7 also functions as part of 
the Shieldin complex that promotes 53BP1 mediated NHEJ in Brca1-deficient cells 
(Ghezraoui, Oliveira et al. 2018), a function that could potentially contribute to PARP inhibitor 
resistance. These activities in the presence of DSBs induced through PARP inhibition 
provide mechanisms to overcome the damage, leading to resistance to PARP targeting 
therapies.  
A third mechanism of resistance to PARPi, specifically in HR-deficient cancer cells, is 
restoration of replication fork stability. One study demonstrated that reduced recruitment of 
the exonuclease MRE11 in BRCA1-deficient cells prevented end resection at these sites and 
promoted fork stability (Ray Chaudhuri, Callen et al. 2016). Reduced recruitment of another 
DNA exonuclease, MUS81, has also been shown to promote stability of replication forks in 
BRCA2-deficient cancers that develop resistance to PARP inhibition (Rondinelli, Gogola et 
al. 2017). Finally, it has been reported that maintenance of replication forks can be regulated 
at the transcriptional level. One study observed that BRCA2-deficient cells treated with 
PARPi overcome therapeutic pressure by down-regulating expression of the transcription 
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expression increases expression of RAD51, enhancing HR activity even in the absence of 
BRCA2 (Clements, Thakar et al. 2018).  
Resistance to PARP inhibition can also arise from altered activity of PARP and 
PARP-associated proteins. One example is loss of poly(ADP-ribose) glycohydrolase (PARG) 
that has been shown to be a major resistance mechanism to PARP inhibition in Brca2-
mutated cells (Gogola, Duarte et al. 2018). Under unperturbed cellular conditions, PARG 
functions to remove poly(ADP-ribose) chains generated by PARP1 at the site of DNA 
damage. PARP inhibitors can either trap PARP1 on the chromatin, leading to stalled 
replication forks and DSBs, or can inhibit the enzymatic activity and prevent generation of 
poly(ADP-ribose) polymers that signal HR-mediated DSB repair (Dziadkowiec, Gasiorowska 
et al. 2016). In the case of the former, PARPi are most effective when PARG is still active in 
order to remove the poly(ADP-ribose) polymers and inhibit HR signaling. When PARG 
activity is lost, the polymers are still present and HR-mediated repair is still functional. This 
residual HR activity can counteract the effect of the PARPi and lead to resistance (Gogola, 
Duarte et al. 2018).   
Together, these studies describe mechanisms of resistance associated with re-
activation of HR activity and provide evidence describing how activity of multiple repair 
pathways can contribute to resistance to DNA repair targeted therapies.  
 
4 Alternative DNA repair targeting therapies for use in colorectal cancer 
The most common chemotherapy agents used for the treatment of CRC induce DNA 
damage that is recognized and repaired by DNA repair pathways. Inherent defects in these 
pathways make CRC cells more sensitive to these treatments, and for tumors that do not 
harbor mutations in DNA repair associated genes, these pathways can be targeted to induce 
a repair defective phenotype. The therapies described in the previous section either target or 
exploit characteristics of DNA repair-deficient CRC cells. However, there are still other 
alternative therapies that target DNA repair mechanisms that have not been studied in the 
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alternative, and potentially novel, treatment regimens that can either take advantage of 
repair defects in CRC cells or induce repair deficiency in CRC tumors and thus make those 
cells more responsive to current chemotherapy agents.  
 
4.1 ATR inhibitors 
Colorectal adenomas exhibit endogenous replication stress (Bartkova, Horejsi et al. 2005), a 
phenotype that can be exploited through therapies that target replication stress signaling 
proteins (Halazonetis, Gorgoulis et al. 2008). One target under investigation is the ataxia 
telangiectasia and Rad3 related (ATR) protein. ATR functions at the sites of replication forks 
and is essential for signaling repair proteins when a cell experiences stress due to DNA 
damage that blocks replication progression. ATR directly interacts with RPA that coats single 
strand DNA generated during replication, and this ability allows ATR to sense stalled 
replication forks and corresponding DNA damage (Zou and Elledge 2003). Additionally, ATR 
functions in conjunction with ATM in response to IR and is required for promoting accurate 
repair of DNA DSB damage (Marechal and Zou 2013). Defects in replication fork protection 
are correlated with sensitivity to ATR inhibitiors (ATRi), and patients who do not exhibit 
defects in HR but have unstable replication forks may benefit from ATRi therapies (Hill, 
Decker et al. 2018). Furthermore, ATRi is also a viable option to target BRCA-deficient 
cancer cells that have acquired resistance to PARPi, by inhibiting the “rewired” HR pathway 
that is promotes resistance to PARP inhibition (Yazinski, Comaills et al. 2017, Haynes, Murai 
et al. 2018). For these reasons, ATR is an attractive target to disrupt DNA repair in cancer 
cells. 
Early investigations into ATRi were performed in breast and ovarian cancer cells. 
Several studies have identified a synthetic lethality with ATRi and ATM- or p53-deficiency 
(Reaper, Griffiths et al. 2011, Toledo, Murga et al. 2011), and this effect is further increased 
when cells are also treated with genotoxic agents (Reaper, Griffiths et al. 2011, Shi, Shen et 
al. 2018). One study reported that the ATRi NU6027 sensitized cells to cisplatin in wild-type 
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most sensitive to temozolomide in combination with NU6027 (Peasland, Wang et al. 2011). 
In addition, ATR inhibition was synthetic lethal in combination with PARPi or in cells that had 
defective HR (through loss of XRCC1) (Peasland, Wang et al. 2011, Sultana, Abdel-Fatah et 
al. 2013). Interestingly, one study reported that inhibition of ATR in BRCA1-depleted cells 
further sensitized the cells to damage induced by cisplatin and veliparib, suggesting that 
ATR inhibition functions independently of BRCA status (Huntoon, Flatten et al. 2013). More 
recent studies have shown that pancreatic ductal adenocarcinoma (PDAC) and various 
gastrointestinal cancer cells that exhibit loss of ATM were more sensitive to ATRi (Min, Im et 
al. 2017, Perkhofer, Schmitt et al. 2017). One study demonstrated that the ATR inhibitor 
AZD6738 induces a synthetic lethal phenotype in ATM-deficient, but not ATM-proficient, 
gastric cancer cells, and in vivo tumor growth of ATM-deficient gastric cell xenografts was 
effectively controlled by treatment with AZD6738 compared with control (Min, Im et al. 2017).  
 Recently, DNA DSB repair has been implicated in regulating the expression of PD-L1 
in cancer cells (Sato, Niimi et al. 2017), and the effect of ATR inhibition on PD-L1 
expression, and consequently on immune surveillance of tumor cells, has been investigated 
(Sun, Yang et al. 2018, Vendetti, Karukonda et al. 2018). A siRNA-mediated screen of DSB 
repair genes found that loss of BRCA2 enhanced expression of PD-L1, specifically in 
response to DSBs induced by IR or PARPi. Furthermore, loss of genes associated with the 
error-prone NHEJ pathway, such as Ku80, substantially enhanced PD-L1 expression in 
response to IR (Sato, Niimi et al. 2017). It was observed that treatment with IR and cisplatin 
significantly increased expression of PD-L1, and that this effect was abrogated when cells 
were also treated with pharmacological inhibitors of ATR. Additionally, decreased PD-L1 
expression in the presence of ATRi led to increased immune surveillance of tumor cells, and 
controlled tumor growth. These data suggest that ATRi would be effective in MMRp cells that 
have increased PD-L1 expression as a mechanism of overcoming immune evasion and re-
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Together, these data suggest that ATR inhibition is most effective when combined 
with genotoxic agents and support the hypothesis that DNA repair defective CRC cells may 
also experience synthetic lethality when treated with ATRi. It would be interesting to test 
ATRi in MMRd preclinical models of mCRCs that are able to evade immune surveillance 
despite high levels of neoantigens. 
 
4.2 CHK1 Inhibitors 
Another key player in the DNA damage response signaling cascade is checkpoint kinase 1 
(CHK1) that directly interacts with ATR in the presence of replication stress during S phase 
and promotes replication fork stabilization (Chen and Poon 2008). Following the same 
principle as ATRi, inhibitors targeting CHK1 (CHK1i) have been developed to inhibit 
replication stress signaling in cancer cells that already exhibit DNA repair defects.    
 Prexasertib is one CHK1i that has been thoroughly investigated in patients with 
squamous cell carcinomas (Hong, Moore et al. 2018), non-small cell lung carcinomas (Sen, 
Tong et al. 2017), and high grade serous ovarian carcinomas (Brill, Yokoyama et al. 2017, 
Lee, Nair et al. 2018), often in combination with other therapies. Early studies demonstrated 
that prexasertib (LY2606368) induced replication catastrophe and DNA damage while 
concomitantly disabling cell cycle checkpoints, ultimately leading to apoptosis. This effect 
was observed in vitro and in vivo in models of acute lymphoblastic leukemia and squamous 
cell carcinoma (King, Diaz et al. 2015, Ghelli Luserna Di Rora, Iacobucci et al. 2016). 
 In the context of CRC, one study investigated the effect of CHK1 inhibition on CRC 
stem cells (Manic, Signore et al. 2018). The authors observed that treatment with 
prexasertib, both in vitro and in vivo, inhibited replication and disabled cell cycle checkpoints, 
causing the cells to enter mitosis prematurely, ultimately leading to apoptosis. Interestingly, 
this effect was observed in cells that harbored KRAS mutations, a subset of CRCs 
particularly difficult to target and treat (Manic, Signore et al. 2018). An independent study 
also observed efficacy of CHK1 inhibition in KRAS mutated lung and colon adenocarcinoma 
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functions in a pathway parallel to CHK1 and is responsible for maintaining cell cycle 
checkpoints in response to stress (Reinhardt, Hasskamp et al. 2010). KRAS mutated cells 
exhibit intrinsic genotoxic stress that leads to constant activation of CHK1 and MK2, and 
inhibition of these proteins induced mitotic catastrophe in vitro, in murine cancer models, and 
in patient derived cells (Dietlein, Kalb et al. 2015).  CHK1 inhibitors might be tested in KRAS-
mutated CRC, a subset that currently has limited therapy options. 
 
4.3 Thiopurines 
Thiopurines are a class of nucleotide analogs that have been used successfully for the 
treatment of childhood leukemias (Karran 2006). Thiopurines are incorporated into DNA 
during replication, leading to DNA base pair mismatches that are removed by MMR proteins 
(Coulthard and Hogarth 2005, Karran 2006, Munshi, Lubin et al. 2014). The effect of the 
thiopurine analog 6-thioguanine (6TG) on cell growth has been tested in CRC cell models. 
MMRd CRC cell lines are resistant to 6TG compared with MMRp counterparts (Carethers, 
Hawn et al. 1996, Yan, Berry et al. 2003). 6TG induces reactive oxygen species (Brem and 
Karran 2012) can trigger activity of BER proteins, suggesting that BER-deficient cells may 
have increased cellular sensitivity to thiopurines. Further studies have also demonstrated 
that HR and FA proteins function to repair thiopurine induced damage (Brem and Karran 
2012), and that cells deficient for HR proteins, such as RAD51D, have increased sensitivity 
to thiopurines (Rajesh, Litvinchuk et al. 2011). These data suggest that this class of 
compounds might be effective in CRC tumors that are MMRp but carry mutations in genes 
associated with HR and BER. 
 
5 Clinical trials of DNA repair inhibitors in colorectal cancer 
Targeting DNA repair in CRC has the potential to further increase the efficacy of current 
therapies, and, as described above, there have been multiple pre-clinical studies 
investigating DNA repair targeting therapies in CRC. None of these therapies have been 
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To date, six clinical trials investigating the efficacy of PARPi in CRC are on-going or have 
been completed. Of the five completed trials, only NCT00912743 has reported results 
(Leichman, Groshen et al. 2016). In this study, the efficacy of olaparib was investigated in 33 
CRC patients stratified by microsatellite status. Thirteen MSI-H and 20 non-MSI-H patients 
were enrolled and treated with olaparib 400mg twice a day. The median of progression free 
survival (PFS) was 61 days for the MSI-H cohort and 55 for the non-MSI-H cohort. Overall 
survival (OS) was reported to be 248 days for the MSI-H cohort and 209.5 days for the non-
MSI-H. There was no statistical significance in the median PFS or OS for non-MSI-H cohort. 
The results of this study suggest that olaparib alone is ineffective in CRC patients regardless 
of microsatellite status, and the authors recommend that further studies investigate the use 
of olaparib in combination with DNA damaging agents for this patient cohort (Leichman, 
Groshen et al. 2016). Importantly, this study was conducted in CRC patients that were not 
enriched for HR deficiency status. 
Multiple clinical trials investigating the efficacy of the ATRi AZD6738 have been 
initiated, and most of these include gastrointestinal malignancies other than CRC. 
NCT01955668 is the only trial that has been completed thus far, and the results of this study 
have not been reported in full. Currently, the majority of clinical trials for AZD6738 focus on 
assessing the efficacy and safety of the drug in patients. As yet, there have not been any 
trials initiated to further elucidate sensitivity of specific cancer subtypes, such as ATM-
deficient tumors, in the clinical setting. In addition to analyzing the efficacy of AZD6738 
alone, several studies are investigating the efficacy of this drug in combination with the 
PARPi olaparib, particularly in patients who were refractory to primary therapies. Once 
completed, these studies have the potential to describe novel therapy regimens can be used 
to treat CRC patients. 
Multiple clinical trials with CHK1 inhibitors are on-going. One trial (NCT02203513) 
has reported results from a cohort of BRCA wild-type high grade serous ovarian cancer 
patients treated with the CHK1 inhibitor prexasertib (Lee, Nair et al. 2018). In this cohort, 
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patients (out of 28) exhibited partial response during the treatment time and one patient died 
during the study due to tumor progression (Lee, Nair et al. 2018). Pre-clinical data that led to 
another ongoing trial (NCT02555644) investigated the efficacy of CHK1 inhibitors in 
combination with EGFR targeted therapies and/or radiotherapy (Zeng, Beggs et al. 2017). In 
this study, prexasertib combined with EGFR targeting therapies significantly decreased cell 
proliferation and delayed tumor growth in both HPV-positive and –negative head and neck 
squamous cell carcinoma mouse models (Zeng, Beggs et al. 2017). These promising results 
provided rationale to test CHK1 inhibitors in combination with both genotoxic and non-
genotoxic therapy regimens for cancer treatment.  
 
6 Concluding remarks 
Standard clinical testing of CRC includes identifying mutations in oncogenes such as KRAS 
and BRAF, as well as characterization of the microsatellite status. Currently, the status of 
DNA repair genes is not investigated in CRCs. However, MSS CRCs carry a higher 
proportion of mutations in HR genes, and defects in this pathway have been associated with 
genomic instability. Whole-genome sequencing analysis of breast cancer samples can 
identify tumors that exhibit genomic rearrangements due to functional deficiencies in 
homologous recombination even BRCA wild-type cells, and these characteristics can be 
used to predict therapy response to PARP inhibitors. We propose that, in addition to genetic 
screening for mutations in known DNA repair genes, identification of gene alterations and 
genomic rearrangements indicative of a repair-defective phenotype should be performed 
systematically in CRC patients. Characterizations based on functional repair deficiency, 
rather than analyses based primarily on genetic alterations, are likely to better predict 
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Figure Legends: 
 
Figure 1. DNA repair pathways with mutated genes highlighted. Left panel: DNA mismatch 
repair pathway recognizes and removes incorrect DNA base pairs generated during 
replication. Right panel: homologous recombination proteins recognize and repair DNA 
double strand breaks. Key proteins in each pathway are shown and the percent of cases that 
carried mutations in these genes are listed (see Table 1 for details).  
 
Figure 2. Therapies targeting cancer specific DNA repair defects. Current chemotherapy 
agents (black) used to treat mCRC. Oxaliplatin induces DNA interstrand crosslinks that are 
repaired by nucleotide excision repair proteins during G1 and by Fanconi Anemia and HR 
proteins during S phase. Irinotecan (SN38) is a topoisomerase inhibitor that induces single 
(SSB) and double strand breaks (DSBs) that are repaired by HR and BER proteins. 5-
fluorouracil is an anti-metabolite that can lead to DNA base pair mismatches repaired by the 
MMR pathway. Alternative therapies (red) that can be used in combination with current 
chemotherapy agents. PARPi and ATRi induce stalled replication forks and DSBs that are 
lethal in cells carrying mutations in HR genes, and CHKi block cell cycle arrest in the 
presence of replication stress. Chemosensitivity can be further induced in cells treated with 
genotoxic agents in combination with targeted therapies. Thiopurines induce DNA base pair 
mismatches that can lead to increased mutational and neoantigen burdens. Anti-PD-1 and 
CTLA-4 immunotherapies target MMRd CRC tumors and are most effective against tumors 
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Table 1. Missense, truncating, and frameshift mutations (putative driver) in DNA damage 
response and repair genes identified in 528 colorectal cancer cases reported in The Cancer 
Genome Atlas Colon Adenocarcinoma (COAD) and Rectal Adenocarcinoma (READ) 
PanCancer Atlas datasets (Liu, Lichtenberg et al. 2018).  Asterisk (*) indicates methylation 
data acquired from the TCGA-COADREAD Provisional dataset. 
 
Gene Cases Affected 
TRP53 92 (17.4%) 
ATM 18 (3.4%) 
BRCA2 10 (1.9%) 
TP53BP1 9 (1.7%) 
MSH6 7 (1.3%) 
ATR 7 (1.3%) 
MTOR 5 (0.9%) 
SMARCB1 4 (0.8%) 
ATRX 3 (0.6%) 
BARD1 3 (0.6%) 
BLM 3 (0.6%) 
MSH3 3 (0.6%) 
BRIP1 2 (0.4%) 
FANCA 2 (0.4%) 
RAD50 2 (0.4%) 
EPC2 1 (0.2%) 
ERCC4 1 (0.2%) 
MLH1 
1 (0.2%) 
 37 (10.3%)* 
MSH2 1 (0.2%) 
PMS2 1 (0.2%) 
RAD21 1 (0.2%) 
RAD21L1 1 (0.2%) 
RAD51C 1 (0.2%) 
SMC1A 1 (0.2%) 
XRCC2 1 (0.2%) 
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Table 2. Clinical trials of PARP, ATR, and CHK1 inhibitors reported to the U.S. National 
Library of Medicine. (https://clinicaltrials.gov/ct2/home). 
Clinical Trials in Colorectal Cancer 





Results Available  
(Leichman, 






























Locally Advanced Rectal Cancer 
Completed  







Metastatic and chemorefractory 
Breast Cancer, Ovarian Cancer, 
Colon Cancer, Lung Cancer, 





    
Clinical Trials in Other Cancers 








Clear Cell Renal Cell Carcinoma, 
Pancreatic Ductal 
Adenocarcinoma, 
 Renal Cell Carcinoma Cancers 












High Grade Serous Carcinoma Recruiting 
NCT02223923 AZD6738 




Chronic Lymphocytic Leukemia, 
Prolymphocytic Leukemia,  







Advanced Solid Malignancies - 
H&N SCC, ATM Pro / Def 
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Head and Neck Squamous Cell 
Carcinoma 
Recruiting 
NCT02576444 AZD6738 Cancer Recruiting 
NCT03527147 AZD6738 
NHL, DLBCL, Non-Hodgkin's 
Lymphoma, Diffuse Large B Cell 
Lymphoma 
Recruiting 





Stage Small Cell Lung Carcinoma 
Recruiting 
NCT02203513 LY2606368 Breast, Ovarian, Prostate  
Recruiting 
(Lee, Nair et al. 
2018) 






Childhood Solid Neoplasm, 
Recurrent Central Nervous 
System Neoplasm, Recurrent 
Malignant Solid Neoplasm, 
Refractory Central Nervous 
System Neoplasm, Refractory 
Malignant Solid Neoplasm 
Recruiting 
NCT02797964 SRA737 







Advanced Solid Tumors Recruiting 




Solid Tumor Recruiting 
NCT01115790 Prexasertib 
Advanced Cancer, Squamous 
Cell Carcinoma, Carcinoma, 
Squamous Cell of Head and 
Neck, Lung Squamous Cell 
Carcinoma, Anal Squamous Cell 
Carcinoma, Carcinoma, Non-






Non-Small Cell Lung Cancer Completed 
NCT02735980 Prexasertib Small Cell Lung Cancer Completed 






Acute Myeloid Leukemia, 
Myelodysplastic Syndromes 
Not yet recruiting 
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